Pfizer Partner to Seek Approval Soon for Vaccine for 5- to 11-Year-Olds: Executives

A vial of Pfizer-BioNTech COVID-19 vaccine is pictured at an Alberta Health Services vaccination clinic in Didsbury, Alberta, on June 29, 2021. (Jeff McIntosh/The Canadian Press)
Share on facebook
Share on twitter
Share on whatsapp
BioNTech, which developed one of the world’s most commonly used COVID-19 vaccines along with Pfizer, is attempting to gain approval soon for vaccinating children between the ages of 5 and 11 across the world, top executives with the firm announced Friday. “Already over the next few weeks we will file the results of our trial in 5- to 11-year-olds with regulators across the world and will request approval of the vaccine in this age group, also here
Subscribe or log in to read the rest of this content.

Subscribe for Newsletter

Sign up to receive important news avoided by other media.

Scroll to Top